Individualized ANH for Non-cardiac Surgery

Launched by WEST CHINA HOSPITAL · May 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a method called individualized acute normovolemic hemodilution (ANH) to see if it can reduce the need for blood transfusions during non-cardiac surgeries where a lot of blood loss is expected. In simpler terms, the researchers want to find out if this technique can help patients avoid needing extra blood during surgery. The study is currently looking for adult participants aged 18 to 75 who are scheduled for elective surgeries and are likely to need more than 8 units of blood.

To be eligible for this trial, patients should have a good level of hemoglobin (a protein in blood that carries oxygen) before surgery—at least 120 grams per liter for men and 110 grams for women. However, certain people, like those who refuse blood transfusions or have serious health issues like heart or kidney problems, won't be able to participate. If you join the trial, you can expect to be part of a well-structured study that aims to improve surgical outcomes and minimize the need for blood transfusions, helping to make surgeries safer for individuals at risk of significant blood loss.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing elective non-cardiac surgery with an anticipated red blood cells transfusion \>8 units (or 1600ml)
• • Aged 18\~75 years
• • Preoperative Hb level \> 120g/L for men and \> 110g/L for women.
• Exclusion Criteria:
• • Refusal of blood transfusion
• • Cardiopulmonary insufficiency
• • Cerebrovascular disease
• • Renal impairment
• • Hemoglobinopathies or blood system diseases
• • Other situations not suitable for inclusion in clinical trial.